Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer

Autores
Lamb, Caroline Ana; Fabris, Victoria Teresa; Jacobsen, Britta M.; Molinolo, Alfredo; Lanari, Claudia Lee Malvina
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
There is a consensus that progestins and thus their cognate receptor molecules, the progesterone receptors (PRs), are essential in the development of the adult mammary gland and regulators of proliferation and lactation. However, a role for natural progestins in breast carcinogenesis remains poorly understood. A hint to that possible role came from studies in which the synthetic progestin medroxyprogesterone acetate was associated with an increased breast cancer risk in women under hormone replacement therapy. However, progestins have also been used for breast cancer treatment and to inhibit the growth of several experimental breast cancer models. More recently, PRs have been shown to be regulators of estrogen receptor signaling. With all this information, the question is how can we target PR, and if so, which patients may benefit from such an approach? PRs are not single unique molecules. Two main PR isoforms have been characterized, PRA and PRB, which exert different functions and the relative abundance of one isoform with respect to the other determines the response of PR agonists and antagonists. Immunohistochemistry with standard antibodies against PR do not discriminate between isoforms. In this review, we summarize the current knowledge on the expression of both PR isoforms in mammary glands, in experimental models of breast cancer and in breast cancer patients, to better understand how the PRA/PRB ratio can be exploited therapeutically to design personalized therapeutic strategies.
Fil: Lamb, Caroline Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Jacobsen, Britta M.. State University of Colorado - Fort Collins; Estados Unidos
Fil: Molinolo, Alfredo. University of California at San Diego; Estados Unidos
Fil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Materia
BREAST CANCER
IN VIVO BREAST CANCER MODELS
ANTIPROGESTINS
ISOFORMS
PATIENT-DERIVED XENOGRAFTS
PR ISOFORM RATIO
PROGESTERONE RECEPTOR
PROGESTINS
PROGNOSTIC MARKERS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/85377
Acceder
id CONICETDig_6fe8f46912b44cc1d7a9ebb74c65b44e
oai_identifier_str oai:ri.conicet.gov.ar:11336/85377
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancerLamb, Caroline AnaFabris, Victoria TeresaJacobsen, Britta M.Molinolo, AlfredoLanari, Claudia Lee MalvinaBREAST CANCERIN VIVO BREAST CANCER MODELSANTIPROGESTINSISOFORMSPATIENT-DERIVED XENOGRAFTSPR ISOFORM RATIOPROGESTERONE RECEPTORPROGESTINSPROGNOSTIC MARKERShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3There is a consensus that progestins and thus their cognate receptor molecules, the progesterone receptors (PRs), are essential in the development of the adult mammary gland and regulators of proliferation and lactation. However, a role for natural progestins in breast carcinogenesis remains poorly understood. A hint to that possible role came from studies in which the synthetic progestin medroxyprogesterone acetate was associated with an increased breast cancer risk in women under hormone replacement therapy. However, progestins have also been used for breast cancer treatment and to inhibit the growth of several experimental breast cancer models. More recently, PRs have been shown to be regulators of estrogen receptor signaling. With all this information, the question is how can we target PR, and if so, which patients may benefit from such an approach? PRs are not single unique molecules. Two main PR isoforms have been characterized, PRA and PRB, which exert different functions and the relative abundance of one isoform with respect to the other determines the response of PR agonists and antagonists. Immunohistochemistry with standard antibodies against PR do not discriminate between isoforms. In this review, we summarize the current knowledge on the expression of both PR isoforms in mammary glands, in experimental models of breast cancer and in breast cancer patients, to better understand how the PRA/PRB ratio can be exploited therapeutically to design personalized therapeutic strategies.Fil: Lamb, Caroline Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Jacobsen, Britta M.. State University of Colorado - Fort Collins; Estados UnidosFil: Molinolo, Alfredo. University of California at San Diego; Estados UnidosFil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaBioScientifica2018-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/85377Lamb, Caroline Ana; Fabris, Victoria Teresa; Jacobsen, Britta M.; Molinolo, Alfredo; Lanari, Claudia Lee Malvina; Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer; BioScientifica; Endocrine - Related Cancer; 25; 12; 12-2018; R605-R6241351-0088CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://erc.bioscientifica.com/view/journals/erc/aop/erc-18-0179.xmlinfo:eu-repo/semantics/altIdentifier/doi/10.1530/ERC-18-0179info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:22:12Zoai:ri.conicet.gov.ar:11336/85377instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:22:12.836CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer
title Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer
spellingShingle Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer
Lamb, Caroline Ana
BREAST CANCER
IN VIVO BREAST CANCER MODELS
ANTIPROGESTINS
ISOFORMS
PATIENT-DERIVED XENOGRAFTS
PR ISOFORM RATIO
PROGESTERONE RECEPTOR
PROGESTINS
PROGNOSTIC MARKERS
title_short Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer
title_full Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer
title_fullStr Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer
title_full_unstemmed Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer
title_sort Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer
dc.creator.none.fl_str_mv Lamb, Caroline Ana
Fabris, Victoria Teresa
Jacobsen, Britta M.
Molinolo, Alfredo
Lanari, Claudia Lee Malvina
author Lamb, Caroline Ana
author_facet Lamb, Caroline Ana
Fabris, Victoria Teresa
Jacobsen, Britta M.
Molinolo, Alfredo
Lanari, Claudia Lee Malvina
author_role author
author2 Fabris, Victoria Teresa
Jacobsen, Britta M.
Molinolo, Alfredo
Lanari, Claudia Lee Malvina
author2_role author
author
author
author
dc.subject.none.fl_str_mv BREAST CANCER
IN VIVO BREAST CANCER MODELS
ANTIPROGESTINS
ISOFORMS
PATIENT-DERIVED XENOGRAFTS
PR ISOFORM RATIO
PROGESTERONE RECEPTOR
PROGESTINS
PROGNOSTIC MARKERS
topic BREAST CANCER
IN VIVO BREAST CANCER MODELS
ANTIPROGESTINS
ISOFORMS
PATIENT-DERIVED XENOGRAFTS
PR ISOFORM RATIO
PROGESTERONE RECEPTOR
PROGESTINS
PROGNOSTIC MARKERS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv There is a consensus that progestins and thus their cognate receptor molecules, the progesterone receptors (PRs), are essential in the development of the adult mammary gland and regulators of proliferation and lactation. However, a role for natural progestins in breast carcinogenesis remains poorly understood. A hint to that possible role came from studies in which the synthetic progestin medroxyprogesterone acetate was associated with an increased breast cancer risk in women under hormone replacement therapy. However, progestins have also been used for breast cancer treatment and to inhibit the growth of several experimental breast cancer models. More recently, PRs have been shown to be regulators of estrogen receptor signaling. With all this information, the question is how can we target PR, and if so, which patients may benefit from such an approach? PRs are not single unique molecules. Two main PR isoforms have been characterized, PRA and PRB, which exert different functions and the relative abundance of one isoform with respect to the other determines the response of PR agonists and antagonists. Immunohistochemistry with standard antibodies against PR do not discriminate between isoforms. In this review, we summarize the current knowledge on the expression of both PR isoforms in mammary glands, in experimental models of breast cancer and in breast cancer patients, to better understand how the PRA/PRB ratio can be exploited therapeutically to design personalized therapeutic strategies.
Fil: Lamb, Caroline Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Fabris, Victoria Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Jacobsen, Britta M.. State University of Colorado - Fort Collins; Estados Unidos
Fil: Molinolo, Alfredo. University of California at San Diego; Estados Unidos
Fil: Lanari, Claudia Lee Malvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
description There is a consensus that progestins and thus their cognate receptor molecules, the progesterone receptors (PRs), are essential in the development of the adult mammary gland and regulators of proliferation and lactation. However, a role for natural progestins in breast carcinogenesis remains poorly understood. A hint to that possible role came from studies in which the synthetic progestin medroxyprogesterone acetate was associated with an increased breast cancer risk in women under hormone replacement therapy. However, progestins have also been used for breast cancer treatment and to inhibit the growth of several experimental breast cancer models. More recently, PRs have been shown to be regulators of estrogen receptor signaling. With all this information, the question is how can we target PR, and if so, which patients may benefit from such an approach? PRs are not single unique molecules. Two main PR isoforms have been characterized, PRA and PRB, which exert different functions and the relative abundance of one isoform with respect to the other determines the response of PR agonists and antagonists. Immunohistochemistry with standard antibodies against PR do not discriminate between isoforms. In this review, we summarize the current knowledge on the expression of both PR isoforms in mammary glands, in experimental models of breast cancer and in breast cancer patients, to better understand how the PRA/PRB ratio can be exploited therapeutically to design personalized therapeutic strategies.
publishDate 2018
dc.date.none.fl_str_mv 2018-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/85377
Lamb, Caroline Ana; Fabris, Victoria Teresa; Jacobsen, Britta M.; Molinolo, Alfredo; Lanari, Claudia Lee Malvina; Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer; BioScientifica; Endocrine - Related Cancer; 25; 12; 12-2018; R605-R624
1351-0088
CONICET Digital
CONICET
url http://hdl.handle.net/11336/85377
identifier_str_mv Lamb, Caroline Ana; Fabris, Victoria Teresa; Jacobsen, Britta M.; Molinolo, Alfredo; Lanari, Claudia Lee Malvina; Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer; BioScientifica; Endocrine - Related Cancer; 25; 12; 12-2018; R605-R624
1351-0088
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://erc.bioscientifica.com/view/journals/erc/aop/erc-18-0179.xml
info:eu-repo/semantics/altIdentifier/doi/10.1530/ERC-18-0179
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv BioScientifica
publisher.none.fl_str_mv BioScientifica
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614212630872064
score 13.069144

Publicaciones similares